120 related articles for article (PubMed ID: 10070309)
21. Medical treatment of neuroendocrine gut and pancreatic tumors.
Oberg K; Eriksson B
Acta Oncol; 1989; 28(3):425-31. PubMed ID: 2472826
[TBL] [Abstract][Full Text] [Related]
22. Induction of interferon regulatory factors 2'-5' oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness.
Fischer T; Aman J; van der Kuip H; Rudolf G; Peschel C; Aulitzky WE; Huber C
Br J Haematol; 1996 Mar; 92(3):595-603. PubMed ID: 8616023
[TBL] [Abstract][Full Text] [Related]
23. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.
Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A
Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548
[TBL] [Abstract][Full Text] [Related]
24. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors.
Oberg K; Eriksson B; Janson ET
Digestion; 1994; 55 Suppl 3():64-9. PubMed ID: 7698540
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the mouse monoclonal antibody TJ4C4 directed at human p68 kinase.
Radosevich JA; Ghadge GD; Haines GK; Malhotra P; Thimmappya B
Tumour Biol; 1994; 15(5):255-62. PubMed ID: 7527582
[TBL] [Abstract][Full Text] [Related]
26. Intervention in gastro-enteropancreatic neuroendocrine tumours.
Baudin E; Planchard D; Scoazec JY; Guigay J; Dromain C; Hadoux J; Debaere T; Elias D; Ducreux M
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):855-65. PubMed ID: 23582924
[TBL] [Abstract][Full Text] [Related]
27. Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors--an antiangiogenic effect?
Dirix LY; Vermeulen PB; Fierens H; De Schepper B; Corthouts B; Van Oosterom AT
Anticancer Drugs; 1996 Feb; 7(2):175-81. PubMed ID: 8740722
[TBL] [Abstract][Full Text] [Related]
28. Signaling to the DEAD box--regulation of DEAD-box p68 RNA helicase by protein phosphorylations.
Yang L; Lin C; Liu ZR
Cell Signal; 2005 Dec; 17(12):1495-504. PubMed ID: 15927448
[TBL] [Abstract][Full Text] [Related]
29. Expression of the double-stranded RNA-dependent protein kinase (p68) in human breast tissues.
Haines GK; Cajulis R; Hayden R; Duda R; Talamonti M; Radosevich JA
Tumour Biol; 1996; 17(1):5-12. PubMed ID: 7501973
[TBL] [Abstract][Full Text] [Related]
30. Expression of the 'dead box' RNA helicase p68 is developmentally and growth regulated and correlates with organ differentiation/maturation in the fetus.
Stevenson RJ; Hamilton SJ; MacCallum DE; Hall PA; Fuller-Pace FV
J Pathol; 1998 Apr; 184(4):351-9. PubMed ID: 9664900
[TBL] [Abstract][Full Text] [Related]
31. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
Kölby L; Persson G; Franzén S; Ahrén B
Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
[TBL] [Abstract][Full Text] [Related]
32. The p68 and p72 DEAD box RNA helicases interact with HDAC1 and repress transcription in a promoter-specific manner.
Wilson BJ; Bates GJ; Nicol SM; Gregory DJ; Perkins ND; Fuller-Pace FV
BMC Mol Biol; 2004 Aug; 5():11. PubMed ID: 15298701
[TBL] [Abstract][Full Text] [Related]
33. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
Strosberg JR; Choi J; Cantor AB; Kvols LK
Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
[TBL] [Abstract][Full Text] [Related]
34. Bacterially expressed recombinant p68 RNA helicase is phosphorylated on serine, threonine, and tyrosine residues.
Yang L; Liu ZR
Protein Expr Purif; 2004 Jun; 35(2):327-33. PubMed ID: 15135410
[TBL] [Abstract][Full Text] [Related]
35. Positron-emission tomography as a radiological technique in neuroendocrine gastrointestinal tumors.
Eriksson B; Lilja A; Ahlström H; Bjurling P; Bergström M; Lindner KJ; Långström B; Oberg K
Ann N Y Acad Sci; 1994 Sep; 733():446-52. PubMed ID: 7978893
[No Abstract] [Full Text] [Related]
36. The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor.
Bates GJ; Nicol SM; Wilson BJ; Jacobs AM; Bourdon JC; Wardrop J; Gregory DJ; Lane DP; Perkins ND; Fuller-Pace FV
EMBO J; 2005 Feb; 24(3):543-53. PubMed ID: 15660129
[TBL] [Abstract][Full Text] [Related]
37. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
von Marschall Z; Scholz A; Cramer T; Schäfer G; Schirner M; Oberg K; Wiedenmann B; Höcker M; Rosewicz S
J Natl Cancer Inst; 2003 Mar; 95(6):437-48. PubMed ID: 12644537
[TBL] [Abstract][Full Text] [Related]
38. Interferons in the management of neuroendocrine tumors and their possible mechanism of action.
Oberg K
Yale J Biol Med; 1992; 65(5):519-29; discussion 531-6. PubMed ID: 1340065
[TBL] [Abstract][Full Text] [Related]
39. Identification of the human DEAD-box protein p68 as a substrate of Tlk1.
Kodym R; Henöckl C; Fürweger C
Biochem Biophys Res Commun; 2005 Jul; 333(2):411-7. PubMed ID: 15950181
[TBL] [Abstract][Full Text] [Related]
40. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome).
de Herder WW
Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):705-15. PubMed ID: 16253895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
